United Therapeutics Rallies After TETON-1 Shows Tyvaso Meets Primary Endpoint in IPF Trial
United Therapeutics shares climbed 12% Monday after the company reported that its pivotal TETON-1 study of nebulized Tyvaso achieved the trial's primary endpoint in patients with idiopathic pulmonary fibrosis (IPF). The therapy produced a statistically significant improvement in absolute forced vital capacity (FVC) versus placebo and reduced the ri…